| 1 |
35164068 | 2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion. | 2022 Jan 26 |
1 |
| 2 |
35425960 | Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. | 2022 Apr 15 |
1 |
| 3 |
32965028 | Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. | 2021 Jan 15 |
1 |
| 4 |
34293664 | Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. | 2021 Sep |
1 |
| 5 |
31787750 | Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer. | 2020 Feb |
1 |
| 6 |
32709856 | Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. | 2020 Jul 24 |
1 |
| 7 |
32833070 | Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies? | 2020 Nov |
1 |
| 8 |
32948057 | Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. | 2020 Sep 16 |
1 |
| 9 |
30940721 | Maintenance Rucaparib Controls Some Pancreatic Cancers. | 2019 Jun |
1 |
| 10 |
31653094 | Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. | 2019 Oct 24 |
1 |
| 11 |
31857852 | Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. | 2019 Dec 10 |
1 |
| 12 |
28454085 | Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. | 2017 Jul 18 |
2 |
| 13 |
27617661 | Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. | 2016 Nov |
1 |
| 14 |
26210103 | Molecular landscape of prostate cancer: implications for current clinical trials. | 2015 Nov |
1 |
| 15 |
26303225 | PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. | 2015 Oct |
1 |
| 16 |
23666017 | Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. | 2013 Jun |
1 |
| 17 |
23922302 | Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. | 2013 Oct 1 |
1 |
| 18 |
20060649 | Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. | 2010 May |
1 |